Patents by Inventor Enli LIU

Enli LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240336699
    Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.
    Type: Application
    Filed: June 21, 2024
    Publication date: October 10, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sonny Oon ANG, Enli LIU, Elizabeth SHPALL, Katy REZVANI
  • Publication number: 20240325443
    Abstract: Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express the T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with bispecific or multi-specific antibodies that are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).
    Type: Application
    Filed: July 22, 2022
    Publication date: October 3, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Enli LIU, Katy REZVANI, Rafet BASAR, Bin LIU, David MARIN COSTA
  • Publication number: 20230159618
    Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.
    Type: Application
    Filed: July 25, 2018
    Publication date: May 25, 2023
    Inventors: Sonny Oon Ang, Enli Liu, Elizabeth Shpall, Katy Rezvani
  • Publication number: 20220325245
    Abstract: Provided herein are methods for expanding NK cells expressing chimeric antigen receptors and/or T cell receptors. Further provided are methods for treating diseases by administering the CAR NK cells.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 13, 2022
    Inventors: Katy Rezvani, Elizabeth Shpall, Enli Liu
  • Publication number: 20220288121
    Abstract: Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant.
    Type: Application
    Filed: August 25, 2020
    Publication date: September 15, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Katy REZVANI, Enli LIU, Elizabeth SHPALL, Rafet BASAR, David MARIN COSTA
  • Patent number: 11154572
    Abstract: The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 26, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Katy Rezvani, Elizabeth Shpall, Enli Liu
  • Publication number: 20210253729
    Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.
    Type: Application
    Filed: April 16, 2021
    Publication date: August 19, 2021
    Inventors: Sonny Oon Ang, Enli Liu, Elizabeth Shpall, Katy Rezvani
  • Publication number: 20200390815
    Abstract: Provided herein are universal antigen presenting cells. Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 17, 2020
    Inventors: Sonny O. T. Ang, Enli Liu, Elizabeth Shpall, Katy Rezvani
  • Publication number: 20180353544
    Abstract: The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.
    Type: Application
    Filed: June 6, 2016
    Publication date: December 13, 2018
    Applicant: Board of Regents, The University of Texas System
    Inventors: Katy REZVANI, Elizabeth SHPALL, Enli LIU